Cargando…

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure

Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharkey, Mark, Babic, Dunja Z., Greenough, Thomas, Gulick, Roy, Kuritzkes, Daniel R., Stevenson, Mario
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044693/
https://www.ncbi.nlm.nih.gov/pubmed/21383975
http://dx.doi.org/10.1371/journal.ppat.1001303
_version_ 1782198757085937664
author Sharkey, Mark
Babic, Dunja Z.
Greenough, Thomas
Gulick, Roy
Kuritzkes, Daniel R.
Stevenson, Mario
author_facet Sharkey, Mark
Babic, Dunja Z.
Greenough, Thomas
Gulick, Roy
Kuritzkes, Daniel R.
Stevenson, Mario
author_sort Sharkey, Mark
collection PubMed
description Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional assays to characterize virus that is maintained during long-term, suppressive ART.
format Text
id pubmed-3044693
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30446932011-03-07 Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure Sharkey, Mark Babic, Dunja Z. Greenough, Thomas Gulick, Roy Kuritzkes, Daniel R. Stevenson, Mario PLoS Pathog Research Article Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional assays to characterize virus that is maintained during long-term, suppressive ART. Public Library of Science 2011-02-24 /pmc/articles/PMC3044693/ /pubmed/21383975 http://dx.doi.org/10.1371/journal.ppat.1001303 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Sharkey, Mark
Babic, Dunja Z.
Greenough, Thomas
Gulick, Roy
Kuritzkes, Daniel R.
Stevenson, Mario
Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title_full Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title_fullStr Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title_full_unstemmed Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title_short Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
title_sort episomal viral cdnas identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044693/
https://www.ncbi.nlm.nih.gov/pubmed/21383975
http://dx.doi.org/10.1371/journal.ppat.1001303
work_keys_str_mv AT sharkeymark episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure
AT babicdunjaz episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure
AT greenoughthomas episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure
AT gulickroy episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure
AT kuritzkesdanielr episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure
AT stevensonmario episomalviralcdnasidentifyareservoirthatfuelsviralreboundaftertreatmentinterruptionandthatcontributestotreatmentfailure